Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer.
Wu L, Liu W, Huang Y, Zhu C, Ma Q, Wu Q, Tian L, Feng X, Liu M, Wang N, Xu X, Liu X, Xu C, Qiu J, Xu Z, Liu W, Zhao Q.
Wu L, et al. Among authors: wang n.
Eur J Med Chem. 2022 Nov 15;242:114701. doi: 10.1016/j.ejmech.2022.114701. Epub 2022 Aug 28.
Eur J Med Chem. 2022.
PMID: 36054949